摘要
目的分析质子泵抑制剂(PPIs)致白细胞减少的相关危险因素,为降低PPIs致白细胞减少风险提供依据。方法采用倾向性评分匹配进行研究,通过医院信息管理系统提取2022年8月至2023年8月在我院使用口服PPIs治疗的2750例患者为研究对象,年龄为18~80岁,根据患者治疗后白细胞减少情况,将其分为正常组2610例,减少组140例。匹配完成后,分析PPIs导致白细胞减少的危险因素。结果倾向性评分匹配成功100对病例,单因素分析显示,患者治疗疗程、累积使用量、用药品种、合并结肠癌、合并胃癌、肝功能、肾功能在两组间的差异具有统计学意义(P<0.05)。Logistics回归分析结果显示年龄、疗程、累积使用量、肝功能异常为PPIs导致白细胞减少的主要危险因素(P<0.05)。结论PPIs总体安全性高,白细胞减少是发生率低的不良反应,临床应对肝功能异常等导致白细胞减少的高危因素重点关注,早期干预,保障用药安全。
Objective To analyze the risk factors associated with leukopenia induced by proton pump inhibitors(PPIs)and reduce the risk of leukopenia.Methods Propensity score matching was used,for 2750 patients aged 18 to 80 treated with PPIs at our hospital between August 2022 and August 2023 from the hospital information system.The patients were divided into two groups based on their post-treatment leukopenia:a normal group(2610 patients)and a leukopenia group(140 patients).Following matching,the risk factors for leukopenia caused by PPIs was analyzed.Results Propensity score was successfully matched 100 patient pairs.The univariate analysis showed significant differences(P<0.05)in the treatment course,cumulative dosage,medication type,concomitant colon cancer,concomitant gastric cancer,liver function,and kidney function between both groups.The logistic regression analysis indicated that age,treatment course,cumulative dosage,and abnormal liver function were the primary factors for the PPIs-induced reduction in white blood cell count(P<0.05).Conclusion The overall safety profile of PPIs is favorable,with leukopenia being a rare adverse event.Clinical management should focus on high-risk factors,such as abnormal liver function,to minimise the risk of leukopenia and ensure medication safety.
作者
潘玉艳
钱晓丹
PAN Yu-yan;QIAN Xiao-dan(Facility of Clinical Trial,The Second People’s Hospital of Changzhou,the Third Affiliated Hospital of Nanjing Medical University,Changzhou Jiangsu 213003;Department of Pharmacy,The Second People’s Hospital of Changzhou,the Third Affiliated Hospital of Nanjing Medical University,Changzhou Jiangsu 213003;Department of Pharmacy,Xuzhou Medical University,Xuzhou Jiangsu 221004)
出处
《中南药学》
2025年第8期2439-2444,共6页
Central South Pharmacy
基金
2020年度江苏省药学会-恒瑞医院药学基金(No.H2020040)。
